Exact Sciences
EXAS
About: Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Employees: 7,000
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
25% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]
21% more capital invested
Capital invested by funds: $7.87B [Q1] → $9.49B (+$1.62B) [Q2]
10% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 90
1% more funds holding
Funds holding: 547 [Q1] → 550 (+3) [Q2]
3% less repeat investments, than reductions
Existing positions increased: 176 | Existing positions reduced: 182
3.2% less ownership
Funds ownership: 97.82% [Q1] → 94.63% (-3.2%) [Q2]
35% less call options, than puts
Call options by funds: $84.9M | Put options by funds: $130M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Financial journalist opinion
Based on 16 articles about EXAS published over the past 30 days
